Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lidocaine+ CPC · 1 trial · 1 indication
100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm)
| Arm | Type | Description |
|---|---|---|
| Lidocaine 8mg +CPC 2mg | EXPERIMENTAL | one single dose |
| Lidocaine 1mg + CPC 2mg | ACTIVE_COMPARATOR | one single dose |
| Name | Type | Description |
|---|---|---|
| Lidocaine 8mg + CPC 2mg | DRUG | one single dose |
| Lidocaine 1mg + CPC 2mg | DRUG | one single dose |
Inclusion Criteria: * Patients with sore throat due to an upper respiratory tract infection, with recent onset (within 48 hours) * Sore throat of at least moderate pain intensity Exclusion Criteria: * \- History of hypersensitivity to any of the study drugs and listed excipients or to drugs of si...
Lidocaine+ CPC is being developed for the treatment of sore throat due to a common cold. It is a small molecule combination product formulated as a sore throat lozenge. The asset is in Phase 3 development, with one completed Phase 3 trial conducted in Germany.
Lidocaine+ CPC targets sodium channel proteins SCN1A, SCN5A, SCN4A, SCN7A, SCN2A, and SCN9A. It is classified as a blocker. By targeting these sodium channels, the combination is designed to interfere with pain signaling associated with sore throat.
Lidocaine+ CPC is being developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical program for this sore throat lozenge.
Lidocaine+ CPC is in Phase 3 development. One Phase 3 trial has been completed, and there are currently no active trials. The completed trial enrolled 250 participants and was randomized, double-blind, and active-controlled.
Lidocaine+ CPC has been studied in one completed Phase 3 trial, NCT01265446. The trial evaluated the efficacy and safety of a sore throat lozenge containing lidocaine and cetylpyridinium chloride in patients with sore throat due to a common cold. It enrolled 250 participants in Germany.